Literature DB >> 22306838

Liver resection for liver metastases from nondigestive endocrine cancer: extrahepatic disease burden defines outcome.

Andreas Andreou1, Antoine Brouquet, Kishore G S Bharathy, Nancy D Perrier, Eddie K Abdalla, Steven A Curley, Matthias Glanemann, Daniel Seehofer, Peter Neuhaus, Jean-Nicolas Vauthey, Thomas A Aloia.   

Abstract

BACKGROUND: For patients with hepatic nondigestive endocrine metastases (HNEM), the role of liver resection is not well-defined.
METHODS: We reviewed outcomes for patients who underwent liver resection for HNEM at 2 centers to identify predictors of survival.
RESULTS: From 1991 to 2010, 51 patients underwent liver resection for HNEM. Primary tumor types were adrenal gland (n = 26), thyroid (n = 11), testicular germ cell (n = 9), and ovarian granulosa cell (n = 5). 28 patients (55%) had synchronous or early (diagnosed within 12 months after primary tumor resection) liver metastases. At liver resection, 26 patients (51%) had extrahepatic metastases, and 7 (14%) had ≥2 sites of extrahepatic metastases. 32 patients (63%) had major liver resection and 19 (37%) had a simultaneous extrahepatic procedure. 90-day postoperative morbidity and mortality rates were 27% and 2%, respectively. After median follow-up of 20 months (range, 1-144), the 5-year overall and recurrence-free survival rates were 58% and 37%, respectively. Survival was not affected by primary tumor type. In multivariate analysis, ≥2 sites of extrahepatic metastases (hazard ratio [HR] = 4.80; 95% confidence interval [CI] = 1.18-19.50; P = .028) and interval of ≤12 months between primary tumor resection and diagnosis of liver metastases (HR = 5.33; 95% CI = 1.11-25.71; P = .037) were associated with worse overall survival after liver resection.
CONCLUSION: For selected patients, liver resection for HNEM is associated with long-term survival. The number of extrahepatic sites of metastasis and the timing of appearance of liver metastases should be considered in patient selection.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22306838      PMCID: PMC3880181          DOI: 10.1016/j.surg.2011.12.025

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  30 in total

1.  Surgical management and emerging therapies to prolong survival in metastatic neuroendocrine cancer.

Authors:  Skye C Mayo; Mechteld C de Jong; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2010-09-17       Impact factor: 5.344

2.  Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients.

Authors:  L E Harrison; M F Brennan; E Newman; J G Fortner; A Picardo; L H Blumgart; Y Fong
Journal:  Surgery       Date:  1997-06       Impact factor: 3.982

3.  Hepatic neuroendocrine metastases: does intervention alter outcomes?

Authors:  R S Chamberlain; D Canes; K T Brown; L Saltz; W Jarnagin; Y Fong; L H Blumgart
Journal:  J Am Coll Surg       Date:  2000-04       Impact factor: 6.113

4.  Is extended hepatectomy for hepatobiliary malignancy justified?

Authors:  Jean-Nicolas Vauthey; Timothy M Pawlik; Eddie K Abdalla; James F Arens; Rabih A Nemr; Steven H Wei; Debra L Kennamer; Lee M Ellis; Steven A Curley
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

5.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Authors:  Siegbert Faiss; Ulrich-Frank Pape; Michael Böhmig; Yvonne Dörffel; Ulrich Mansmann; Werner Golder; Ernst Otto Riecken; Bertram Wiedenmann
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

6.  Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

Authors:  Felix G Fernandez; Jeffrey A Drebin; David C Linehan; Farrokh Dehdashti; Barry A Siegel; Steven M Strasberg
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

7.  Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma.

Authors:  P Tauzin-Fin; M Sesay; P Gosse; P Ballanger
Journal:  Br J Anaesth       Date:  2004-02-06       Impact factor: 9.166

Review 8.  Metastatic inefficiency: the scientific basis for resection of liver metastases from colorectal cancer.

Authors:  P H Sugarbaker
Journal:  J Surg Oncol Suppl       Date:  1993

9.  Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

Authors:  Eddie K Abdalla; Jean-Nicolas Vauthey; Lee M Ellis; Vickie Ellis; Raphael Pollock; Kristine R Broglio; Kenneth Hess; Steven A Curley
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more
  2 in total

Review 1.  Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.

Authors:  R Dadu; M E Cabanillas
Journal:  Minerva Endocrinol       Date:  2012-12       Impact factor: 2.184

2.  The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma.

Authors:  Daniel Puhr-Westerheide; Clemens C Cyran; Josef Sargsyan-Bergmann; Andrei Todica; Franz-Josef Gildehaus; Wolfgang G Kunz; Robert Stahl; Christine Spitzweg; Jens Ricke; Philipp M Kazmierczak
Journal:  Cancer Imaging       Date:  2019-11-14       Impact factor: 3.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.